Skin toxicities compromise prolonged pemetrexed treatment

Journal of Thoracic Oncology

Volumn 6, Issue 12, 2011, Pages 2083-2089

  Eguia, Belen ^a   Ruppert, Anne Marie ^a   Fillon, Julie ^a   Lavolé, Armelle ^a   Gounant, Valérie ^a   Epaud, Christelle ^a   Milleron, Bernard ^a   Moguelet, Philippe ^a   Wislez, Marie ^a   Frances, Camille ^a   Cadranel, Jacques ^a  

^a HÔPITAL TENON   (France)

Author keywords

Conjunctivitis; Cutaneous side effect; Edema of the limbs; Lung cancer; Pemetrexed; Periorbital edema; Scleroderma

Indexed keywords

PEMETREXED;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PATIENT REFERRAL; PERIORBITAL EDEMA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SEX RATIO; SKIN TOXICITY;

EID: 81755171982     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31822e722f     Document Type: Article

References (29)

1. Villela L, Stanford B, Shah S. Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Pharmacotherapy 2006;26:641-654. (Pubitemid 43673047)
2. Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (alimta). Oncologist 2004;9:482-488. (Pubitemid 39332311)
3. Russo F, Bearz A, Pampaloni G. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic nonsmall cell lung cancer. BMC Cancer 2008;8:216.
4. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
5. Hanna N, Shepherd F, Fossella F, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
6. Niyikiza C, Baker S, Seitz D, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
7. Niyikiza C, Hanauske A, Rusthoven J, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002;29:24-29. (Pubitemid 36176671)
8. Clarke S, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (alimta, ly231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-741. (Pubitemid 34567380)
9. Kurata T, Tamura K, Okamoto I, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2006;54:241-242. (Pubitemid 44764924)
10. Guhl G, Diaz-Ley B, Sanchez-Perez J, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2010;69:249-250.
11. Bastos D, Calabrich A, Katz A. Pemetrexed-induced fluid retention. J Thorac Oncol 2010;5:752.
12. Tummino C, Barlesi F, Tchouhadjian C, et al. Severe cutaneous toxicity after pemetrexed as second line treatment for a refractory non small cell lung cancer. Rev Mal Respir 2007;24:635-638. (Pubitemid 46841661)
13. Bosch-Barrera J, Gaztañaga M, Ceballos J, et al. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer. Onkologie 2009;32:580-584.
14. Hureaux J, Le Guen Y, Tuchais C, et al. Radiation recall dermatitis with pemetrexed. Lung Cancer 2005;50:255-258. (Pubitemid 41427901)
15. Barlési F, Tummino C, Tasei A, et al. Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer 2006;54:423-425. (Pubitemid 44740264)
16. Lopes G, Vincek V, Raez L. Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006;51:247-249. (Pubitemid 43144368)
17. Brambilla E, Travis W, Colby T, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-1068. (Pubitemid 34092881)
18. Groome P, Bolejack V, Crowley J, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the t, n, and m descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:694-705. (Pubitemid 47357521)
19. Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med 2010;362:865-869.
20. Aapro M, Martin C, Hatty S. Gemcitabine-a safety review. Anticanc Drugs 1998;9:191-201.
21. Zimmerman G, Keeling J, Burris H, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131: 202-206.
22. Battafarano D, Zimmerman G, Older S, et al. Docetaxel (taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 1995;76:110-115.
23. Chu C, Yang C, Chiu H. Gemcitabine-induced acute lipodermatosclerosis- like reaction. Acta Derm Venereol 2001;81:426-428. (Pubitemid 34112321)
24. Bessis D, Guillot B, Legouffe E, et al. Gemcitabine-associated scleroderma-like changes of the lower extremities. J Am Acad Dermatol 2004;51:S73-S76.
25. Cleveland M, Ajaikumar B, Reganti R. Cutaneous fibrosis induced by docetaxel: a case report. Cancer 2000;88:1078-1081. (Pubitemid 30127669)
26. Nicolson T, Mellor H, Roberts R. Gender differences in drug toxicity. Trends Pharmacol Sci 2010;31:108-114.
27. Miller M. Gender-based differences in the toxicity of pharmaceuticals-the food and drug administration's perspective. Int J Toxicol 2001;20: 149-152. (Pubitemid 32646165)
28. Tonkinson JL, Wagner MM, Paul DC, et al. Cell cycle modulation by the multitargeted anti-folate, ly231514, increases the antiproliferative activity of gemcitabine. Proc Am Assoc Cancer Res 1996;37:370 (abstract 2523).
29. Gabrielli A, Avvedimento E, Krieg T. Scleroderma. N Engl J Med 2009;360:1989-2003.